Abstract: Methods for assessing the efficacy of Seralutinib treatment for PAH in subjects suffering from PAH are provided, as well as methods for increasing the ratio of the volume of distal pulmonary arteries relative to the volume of proximal pulmonary arteries (BV510ARatio) by administering to the subject an effective amount of Seralutinib. Also provided are methods for increasing the pulmonary vascular volume of small arterial vessels, as well as decreasing the dilation of larger pulmonary arterial vessels, in a subject in need thereof by administering to the subject an effective amount of Seralutinib.

Abstract: Asthma creates inflation of the epithelial cells in the airway of a patient. Inflammation causes epithelial cells to increase the production of nitric oxide far above the normally low levels. Therefore, clinicians can detect biomarkers of Asthma and other maladies by measuring the concentration of exhaled nitric oxide (“eNO”) for fractional exhaled nitric oxide (“FeNO”). However, current systems require the patient to exhale at a constant rate to estimate the concentration eNO. This rough approximation may under or overestimate the FeNO, which can cause misdiagnosis. Accordingly, disclosed are systems and methods to determine the amount of nitric oxide exhaled that compensate for a variable flow rate of exhaling, and do not assume a constant flow rate.